Haloperidol depot test dose

An assessment for an underlying cause of behavior is needed before prescribing antipsychotic medication for symptoms of dementia . [32] Antipsychotics in old age dementia showed a modest benefit compared to placebo in managing aggression or psychosis, but this is combined with a fairly large increase in serious adverse events. Thus, antipsychotics should not be used routinely to treat dementia with aggression or psychosis, but may be an option in a few cases where there is severe distress or risk of physical harm to others. [33] Psychosocial interventions may reduce the need for antipsychotics. [34]

Antipsychotic agents, particularly IV haloperidol, used in the management of delirium have been associated with lengthening of the QT interval, possibly leading to atypical ventricular tachycardia (torsades de pointes), ventricular fibrillation, and sudden death. The manufacturer of Haldol and the US Food and Drug Administration (FDA) state that although injectable haloperidol is approved only for IM injection and not for IV administration , there is considerable evidence from the medical literature that IV administration of the drug is a relatively common, unlabeled (''off-label'') clinical practice, principally for the treatment of severe agitation in intensive care units, and recommend ECG monitoring in any patient receiving the drug IV. Many clinicians also recommend that baseline and periodic or continuous ECG monitoring be performed with special attention paid to the length of the QT c interval. Prolongation of the QT c interval to greater than 450 msec or to greater than 15-25% over that in previous ECGs may warrant telemetry, a cardiology consultation, and dose reduction or discontinuance. Serum concentrations of magnesium and potassium also should be monitored at baseline and periodically in critically ill patients, especially those with baseline QT c intervals of 440 msec or longer, those receiving other drugs known to increase the QT interval, and those who have electrolyte disorders. Limited evidence suggests that the incidence of torsades de pointes in patients receiving haloperidol IV is about -%, but may increase to greater than 10% at relatively high IV doses (., 35 mg or more over 24 hours). (See Cautions: Cardiovascular Effects and also see Cautions: Precautions and Contraindications.)

Haloperidol depot test dose

haloperidol depot test dose


haloperidol depot test dosehaloperidol depot test dosehaloperidol depot test dose